Holdings A/S Novo Sells 176,647 Shares of KalVista Pharmaceuticals, Inc. (KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Holdings A/S Novo sold 176,647 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $7.21, for a total transaction of $1,273,624.87. Following the sale, the insider now owns 2,876,027 shares of the company’s stock, valued at $20,736,154.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Holdings A/S Novo also recently made the following trade(s):

  • On Thursday, September 14th, Holdings A/S Novo sold 10,000 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $8.05, for a total transaction of $80,500.00.
  • On Wednesday, September 13th, Holdings A/S Novo sold 25,900 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $8.02, for a total transaction of $207,718.00.

Shares of KalVista Pharmaceuticals, Inc. (KALV) opened at 6.96 on Friday. The stock’s market capitalization is $67.60 million. The stock’s 50 day moving average is $8.20 and its 200-day moving average is $7.83. KalVista Pharmaceuticals, Inc. has a one year low of $6.09 and a one year high of $10.65.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.08. The company had revenue of $0.10 million for the quarter. KalVista Pharmaceuticals had a negative return on equity of 57.41% and a negative net margin of 4,191.47%. On average, equities research analysts expect that KalVista Pharmaceuticals, Inc. will post ($2.94) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Holdings A/S Novo Sells 176,647 Shares of KalVista Pharmaceuticals, Inc. (KALV) Stock” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at

KALV has been the subject of a number of recent research reports. BTIG Research initiated coverage on shares of KalVista Pharmaceuticals in a report on Thursday, August 31st. They set a “buy” rating and a $18.00 price target for the company. ValuEngine upgraded shares of KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 2nd.

An institutional investor recently bought a new position in KalVista Pharmaceuticals stock. Eventide Asset Management LLC bought a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 98,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $766,000. Eventide Asset Management LLC owned 1.01% of KalVista Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 75.66% of the company’s stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply